Basilea Pharmaceutica – executive interview

In this interview, CEO David Veitch and CFO Adesh Kaul discuss Basilea Pharmaceutica’s strong H125 performance and the company’s key growth drivers. They outline the reasons for Cresemba’s continued strong momentum and Basilea’s strategy for growth beyond its lead asset’s maturity. They discuss Zevtera (recently launched in the US), fosmanogepix (on track for a new drug application filing in 2028) and the recently acquired oral antibacterial, ceftibuten-ledaborbactam etzadroxil, which together are the next growth drivers for Basilea. They also touch on the recent macroeconomic uncertainty in the US and how Basilea remains confident in its association with BARDA, which materially de-risks its R&D efforts. Finally, they discuss the key upcoming catalysts and milestones for the company over the next 12–18 months.

Basilea Pharmaceutica is a Switzerland-based, commercial-stage, profitable biotech focused on treating serious infectious diseases. It has a broad product portfolio led by marketed products Cresemba and Zevtera, therapeutic agents against severe fungal infection and drug-resistant strains of bacteria (eg MRSA). The company has been steadily building its asset pipeline, which now includes fosmanogepix (a novel broad-spectrum antifungal, currently in Phase III), ceftibuten-ledaborbactam etzadroxil (a Phase III-ready novel and orally administered antibiotic) and two preclinical assets, BAL2062 and BAL2420.